Document:

brk_ex101.htm

EXHIBIT 10.1
 
PATENT ASSIGNMENT
AND
TECHNOLOGY TRANSFER AGREEMENT
 
This PATENT ASSIGNMENT AND TECHNOLOGY TRANSFER AGREEMENT ("Agreement") is entered into on May 6, 2016 ("Effective Date") by and between iSee Automation Inc., a corporation organized and existing under the laws of Canada ("Seller"), and BRK, Inc., a corporation organized and existing under the laws of Nevada ("Purchaser"). The parties hereby agree as follows:
 
1. Background.
 
1.1 Seller owns certain United States Patent applications and/or related foreign patents and applications. 
 
1.2 Seller wishes to sell its right, title and interest in such patents applications and related know-how, technology and plan for commercializing the same to Purchaser. 
 
1.3 Purchaser wishes to purchase such patents applications and related know-how, technology and plan for commercializing. 
 
2. Definitions. Certain terms are defined in the text of this Agreement, and in addition, the following terms shall have the following definitions:
 
2.1 "Closing Date"means the date on which Purchaser shall transfer title to the Patents (as defined below) and Subject Technology (as defined below) to Purchaser. 
 
2.2 "Patents" means those patents and applications listed in Exhibit A hereto, and all reissues, reexaminations, extensions, continuations, continuations in part, continuing prosecution applications, and divisions of such patents and applications; provisional patent applications that are or will be continuations or continuations in part of such patents and applications; and foreign counterparts to any of the foregoing including without limitation utility models. 
 
2.3 "Subject Technology" means: (i) all technology, know-how, methods, documents, materials, and all confidential information as of the Effective Date relating to the invention, a Helmet System, but not the subject of the Patents, and the idea and plan to commercialize the same to and the Patents to generate revenues.
 
3. Delivery and Payment. 
 
3.1 Delivery. On the Effective Date, Seller shall deliver a notarized and executed original of the Patent Assignment in Exhibit B hereto to Purchaser. 
 
	 
	1

	

	 

 
3.2 Consideration for transfer of Patents and Subject Technology. 
 
(a) Purchaser shall pay Seller five million (5,000,000) shares of common stock of Purchaser.
 
(b) All consideration payable and otherwise due to Seller under this Section 3 shall not be reduced or otherwise made be made less even if the United States Patent and Trademark Officer or any other patent office or authority does not grant patent right to any invention underlying patent application. 
 
4. Transfer of Patents and Subject Technology. 
 
4.1 Patent and Subject Technology Assignment. Effective on the Closing Date, Seller hereby sells, assigns, transfers and conveys to Purchaser all right, title and interest it has in and to the Patents and Subject Technology and all inventions and discoveries described therein. 
 
4.2 Assignment of Causes of Action. Effective on the Closing Date, Seller hereby sells, assigns, transfers and conveys to Purchaser all right, title and interest it has in and to all causes of action and enforcement rights, whether currently pending, filed, or otherwise, for (i) the Patents and all inventions and discoveries described therein, including without limitation all rights to pursue damages, injunctive relief and other remedies for past, current and future infringement of the Patents, and (ii) the Subject Technology.
 
5. Additional Obligations.
 
5.1 Further Assurances. At the reasonable request of Purchaser and without demanding further consideration from Purchaser, Seller agrees to execute and deliver such other instruments and do and perform such other acts and things as may be reasonably necessary for effecting completely the consummation of the transfer of ownership in and to the Patents as contemplated hereby, including without limitation execution, acknowledgment and recordation of other such papers, and using all reasonable best efforts to obtain the same from the respective inventors, as necessary or desirable for fully perfecting and conveying unto Purchaser the benefit of the transfer of ownership in and to the Patents as contemplated hereby. 
 
5.2 Further Assistance. Subject to the terms and conditions hereof, Seller agrees, upon the reasonable request of Purchaser, to do all things necessary, proper, or advisable, including without limitation the execution, acknowledgment and recordation of specific assignments, oaths, declarations and other documents on a country-by-country basis, to assist Purchaser in obtaining, perfecting, sustaining, and/or enforcing the Patent Rights. Such assistance may also include providing, and obtaining from the respective inventors, prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, powers of attorney, specifications, declarations or other papers and other assistance reasonably necessary for filing patent applications, complying with any duty of disclosure, and conducting prosecution, reexamination, reissue, interference or other priority proceedings, opposition proceedings, cancellation proceedings, public use proceedings, infringement or other court actions and the like with respect to the Patent Rights. Seller's agreement to render any of the foregoing assistance is subject to Purchaser's payment of all reasonable expenses of Seller incurred in connection therewith and the availability of Seller's personnel. 
 
	 
	2

	

	 

 
6. Representations and Warranties.
 
Seller hereby warrants to Purchaser as follows: 
 
6.1 Authority. Seller has the right and authority to enter into this Agreement and to carry out its obligations hereunder. 
 
6.2 Title and Contest. Seller has good and marketable title to (i) the Patents, including without limitation all rights, title, and interest in the Patents to sue for infringement thereof, and (ii) the Subject technology. The Patents are free and clear of all liens, mortgages, security interests or other encumbrances, and restrictions on transfer. There are no actions, suits, claims or proceedings threatened, pending or in progress on the part of any named inventor of the Patents relating in any way to the Patents and Seller has not received notice of (and Seller is not aware of any facts or circumstances which could reasonably be expected to give rise to) any other actions, suits, investigations, claims or proceedings threatened, pending or in progress relating in any way to the Patents. There are no existing contracts, agreements, options, commitments, proposals, bids, offers, or rights with, to, or in any person to acquire any of the Patents. 
 
6.3 Existing Licenses. No rights or licenses have been granted under the Patents or the Subject Technology. 
 
6.4 Restrictions on Rights. Purchaser will not be subject to any covenant not to sue or similar restrictions on its enforcement or enjoyment of the Patents or the Subject Technology as a result of the transaction contemplated in this Agreement, or any prior transaction related to the Patents or the Subject Technology. 
 
6.5 Conduct. To Seller's knowledge, none of Seller or its representatives has engaged in any conduct, or omitted to perform any necessary act, the result of which would invalidate any of the Patents or hinder their enforcement, including but not limited to misrepresenting Seller's patent rights to a standard-setting organization. 
 
6.6 Enforcement. Seller has not put a third party on notice of actual or potential infringement of any of the Patents or considered enforcement action(s) with respect to any of the Patents. 
 
6.7 Patent Office Proceedings. None of the Patents have been or are currently involved in any reexamination, reissue, interference proceeding, or any similar proceeding and that no such proceedings are pending or threatened. 
 
6.8 Related Assets. There are no other patents issued and/or applications pending for or on behalf of Seller which are subject to a "Terminal Disclaimer" under 37 C.F.R. §1.321 that require any of such patents issued and/or applications and any of the Patents conveyed in this Agreement to remain under common ownership.
 
	 
	3

	

	 

 
6.9 Fees. All maintenance fees, annuities, and the like due on the Patents have been timely paid through the Effective Date.
 
6.10 Validity and Enforceability. To Seller's knowledge, the Patents have never been found invalid or unenforceable for any reason in any administrative, arbitration, judicial or other proceeding, and Seller has not received any notice or information of any kind from any source suggesting that the Patents may be invalid or unenforceable. 
 
7. Miscellaneous. 
 
7.1 No Representation or Warranty. Seller makes no representations or warranties whatsoever that any of the patents covered by this agreement are either valid or are infringed by any other parties. 
 
7.2 Limitation on Consequential Damages. Except in the case of fraud by seller, neither party shall be liable to the other for loss of profits, or any other indirect or special, consequential, punitive or incidental damages, however caused, even if advised of the possibility of such damage. The parties acknowledge that these limitations on potential liabilities were an essential element in setting consideration under this agreement.
 
7.3 Limitation of Liability. Except in the case of fraud by seller, in no event shall either party's total liability under this agreement exceed the purchase price. The parties acknowledge that these limitations on potential liabilities were an essential element in setting consideration under this agreement. 
 
7.4 Compliance with Laws. Notwithstanding anything contained in this Agreement to the contrary, the obligations of the parties shall be subject to all laws, present and future, of any government having jurisdiction over the parties and this transaction, and to orders, regulations, directions or requests of any such government. 
 
7.5 Confidentiality of Terms. The parties hereto shall keep the terms and existence of this Agreement and the identities of the parties hereto confidential and shall not now or hereafter divulge any of this information to any third party except: (a) with the prior written consent of the other party, such consent shall not be unreasonably withheld; (b) as otherwise may be required by law or legal process, including in confidence to financial advisors in their capacity of advising a party in such matters; (c) during the course of litigation, so long as the disclosure of such terms and conditions are restricted in the same manner as is the confidential information of other litigating parties; or (d) in confidence to its legal counsel, accountants, banks and financing sources and their advisors solely in connection with complying with financial transactions; provided that, in (b) through (d) above, (i) the disclosing party shall use all legitimate and legal means available to minimize the disclosure to third parties, including without limitation seeking a confidential treatment request or protective order whenever appropriate or available; and (ii), other than disclosures pursuant to subsection (d) above, the disclosing party shall provide the other party with at least ten (10) days prior written notice of such disclosure. The above notwithstanding, Purchaser agrees that, on or after the Effective Date, Seller shall be allowed to make one or more public announcements in order to fulfill its requirements as a public company with respect to the disclosure of this Agreement. Seller agrees that it will submit any such announcements to Purchaser at least two (2) days prior to its making those announcements for Purchaser's approval, which approval shall not be unreasonably withheld. 
 
	 
	4

	

	 

 
7.6 Governing Law. Any claim arising under or relating to this Agreement shall be governed by the internal substantive laws of the State of Washington without regard to principles of conflict of laws. 
 
7.7 Jurisdiction. Each party hereby agrees to jurisdiction and venue in the courts of the State of Washington or the Federal courts sitting therein for all disputes and litigation arising under or relating to this Agreement. 
 
7.8 Entire Agreement. The terms and conditions of this Agreement, including its exhibits, constitutes the entire agreement between the parties with respect to the subject matter hereof, and merges and supersedes all prior and contemporaneous agreements, understandings, negotiations and discussions. Neither of the parties shall be bound by any conditions, definitions, warranties, understandings, or representations with respect to the subject matter hereof other than as expressly provided herein. The section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. No oral explanation or oral information by either party hereto shall alter the meaning or interpretation of this Agreement. No amendments or modifications shall be effective unless in a writing signed by authorized representatives of both parties. These terms and conditions will prevail notwithstanding any different, conflicting or additional terms and conditions which may appear on any purchase order, acknowledgment or other writing not expressly incorporated into this Agreement. This Agreement may be executed in two (2) or more counterparts, all of which, taken together, shall be regarded as one and the same instrument. The following exhibits are attached hereto and incorporated herein: Exhibit A(entitled "Patent Rights to be Assigned") and Exhibit B(entitled "Assignment of Patent Rights"). 
 
7.9 Notices: All notices required or permitted to be given hereunder shall be in writing, shall make reference to this Agreement, and shall be delivered by hand, or dispatched by prepaid air courier or by registered or certified airmail, postage prepaid, addressed as follows: 
 
	In the case of Seller:
	In the case of Purchaser: 

	  
	 

	iSee Automation Inc.
130 King Street West, Suite 1800
Toronto, Ontario
Canada M5X 1E3
	BRK, Inc.
112 North Curry Street
Carson City, Nevada 89703
United States

 
Such notices shall be deemed served when received by addressee or, if delivery is not accomplished by reason of some fault of the addressee, when tendered for delivery. Either party may give written notice of a change of address and, after notice of such change has been received, any notice or request shall thereafter be given to such party at such changed address. 
 
	 
	5

	

	 

 
7.10 Relationship of Parties. The parties hereto are independent contractors. Neither party has any express or implied right or authority to assume or create any obligations on behalf of the other or to bind the other to any contract, agreement or undertaking with any third party. Nothing in this Agreement shall be construed to create a partnership, joint venture, employment or agency relationship between Seller and Purchaser. 
 
7.11 Equitable Relief. Each party agrees that damages alone would be insufficient to compensate the other for any material breach of this Agreement, acknowledges that irreparable harm would result from a breach of this Agreement, and consents to the entering of an order for injunctive relief to prevent a breach or further breach, and the entering of an order for specific performance to compel performance of any obligations under this Agreement. 
 
7.12 Severability. The terms and conditions stated herein are declared to be severable. If any paragraph, provision, or clause in this Agreement shall be found or be held to be invalid or unenforceable in any jurisdiction in which this Agreement is being performed, the remainder of this Agreement shall be valid and enforceable and the parties shall use good faith to negotiate a substitute, valid and enforceable provision which most nearly effects the parties' intent in entering into this Agreement. 
 
7.13 Waiver. Failure by either party to enforce any term of this Agreement shall not be deemed a waiver of future enforcement of that or any other term in this Agreement or any other agreement that may be in place between the parties. 
 
7.14 Assignment. The terms and conditions of this Agreement shall inure to the benefit of Purchaser, its successors, assigns and other legal representatives. Seller shall be entitled to assign this Agreement to, and the terms and condition hereof shall inure to the benefit of, any successor in interest to all or substantially all of the business or assets of Seller (whether by merger, reorganization, asset sale, or otherwise) that assumes all of Seller's obligations under this Agreement. Purchaser shall be provided written notice of any such assignment within one hundred and twenty (120) days of the effective date of such assignment, which notice shall include the name and business address of the relevant assignee. Purchaser Seller shall not be entitled to assign this Agreement without the written consent of Seller.
 
[signature page follows]
 	 
	6

	

	 

    In witness whereof, the parties have executed this Patent Purchase Agreement as of the Effective Date: 
 
	Seller:
	Purchaser:

	 	 
			 
	
	ISEE AUTOMATION INC.
	BRK, INC.

	 	 
	 		 
	
	By: 	/s/ Chris Stramacchia
		By: 	/s/ Brain Keasberry
	
	Name:
	Chris Stramacchia
		Name: 
	Brain Keasberry
	
	Title: 	CEO
		Title: 	President
	

 
	 
	7

	

	 

 
EXHIBIT A 
 
Patent Rights to Be Assigned 
 
	Patent Application No.
	 
	Publication or Filing Date
	 
	Title and Inventor(s)

	US 15/079,847
	 
	Pub. Date: March 24, 2016
	 
	A Helmet System
 
Christopher Stramacchia

 

 
 
 
 
 
     
	 
	8

	

	 

 
EXHIBIT B
 
PATENT ASSIGNMENT
 
WHEREAS, iSee Automation Inc., a corporation organized and existing under the laws of Canada, with an address at 130 King Street West, Suite 1800, Toronto, Ontario, Canada M5X 1E3 ("Assignor") owns all right, title and interest in and to the patents and/or patent applications identified in Exhibit A attached hereto, including the inventions described therein and the patents issued and reissued thereon (collectively, the "Patents"), the renewals therefor and all claims for past or future infringement thereof. 
 
WHEREAS, BRK, Inc., a Nevada corporation with an address at 112 North Curry Street, Carson City, Nevada 89703 ("Assignee"), and Assignor have entered into a Patent Assignment and Technology Transfer Agreement (the "Agreement") dated May 6, 2016, under which Assignor agreed to sell and Assignee agreed to purchase certain assets of Assignor, including the aforesaid Patents, and the applications and renewals therefor and all claims for past or future infringement thereof. 
 
NOW THEREFORE, for valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign, convey and transfer unto Assignee, its successors and assigns, free and clear of any and all liens, restrictions, claims and encumbrances, Assignor's entire right, title, and interest in and to the Patents and divisions, continuations or continuations-in-part thereof, together with all rights of registration, maintenance, and protection thereof in any form, all rights to income, royalties, damages and payments now due or hereafter due or payable in respect thereto, and all rights of recovery and of legal action for past or future infringements and of interference proceedings and reexaminations involving such Patents. 
 
This Assignment is deemed to be executed and delivered within the State of Washington, and it is the intention of the parties that it shall be construed, interpreted and applied in accordance with the laws of the State of Washington without regard to its conflicts of law principles. 
 
[SIGNATURES ON FOLLOWING PAGE]
 
	 
	9

	

	 

 
(SIGNATURE PAGE TO PATENT ASSIGNMENT)
 
IN WITNESS WHEREOF, Assignor has duly executed this Assignment on this ____ day of May, 2016. 
  
	ISEE AUTOMATION INC. 
	
	 			 
	By:			
	Name:
			 
	Title:			 

  
	State or Province of _________________________________
	)
		) ss.: 

	County or City of ___________________________________
	)

On this     day of May 2016, before me, _____________________, personally appeared ____________, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument. 
IN WITNESS WHEREOF, I have hereunto set my hand and official seal. 
 
Notary Public                                                                         
 
My Commission expires:                                           
 
Notarial Seal 
 	 
	10

	

	 

    EXHIBIT A
 
PATENT APPLICATIONS 
 
	U.S. Patent Application Serial No.
	 
	Date filed
	 
	Title of Invention

	15/079,847
	 
	March 24, 2016
	 
	A Helmet System

 
 
 
 
 
 
 
 
 
 
 
11EX-10.34

 Exhibit 10.34 
  

					
	 

	 	 Bioventus LLC
 4721 Emperor Blvd.,
Suite 100
 Durham, NC 27703
 USA
	  	 1-919-474-0700
 1-000-300-4325

www.BioventusGlobal.com

 July 20, 2016 
  

	Re:	Employment Terms 

 Dear Tony: 

This letter agreement (the “Agreement”) sets forth the terms of your continued employment at Bioventus LLC
(“Bioventus” or the “Company”). This Agreement will be effective on the effective date of the initial public offering of Bioventus Inc. common stock (the “IPO”) and will
supersede in its entirety that certain offer letter entered into by and between you and Bioventus LLC dated November 4, 2013. 
 Employment and
Duties 
 You will continue to be employed in the role of Chief Executive Officer of the Company and you shall perform the duties of this role as
are customary and as may be required by Bioventus. In addition, you shall serve as Chief Executive Officer of Bioventus Inc. You will report to the Board of Directors of Bioventus Inc. (the “Board”), and you will be
based at the headquarters of Bioventus currently located in Durham, NC. 
 In addition, and without further compensation, you will be appointed to serve as
a member of the Board on or prior to the IPO and, during the period of your employment as Chief Executive Officer of the Company, the Company shall propose you for reelection to the Board at the expiration of any applicable term of Board service.
You shall have such duties and responsibilities, commensurate with your position, as may be reasonably assigned to you from time to time by the Board, or which are in accordance with the delegations of authority set out by the Board. 

During your employment with Bioventus, you will devote your full-time best efforts and business time and attention to the business of Bioventus. The Board
will allow you to continue your current participation on the board of directors of two companies other than Bioventus. Any additional or other board or committee participation requires the approval of the Board. 

At-Will Employment Relationship 
 You may terminate your
employment with Bioventus at any time and for any reason whatsoever simply by notifying Bioventus. Likewise, Bioventus may terminate your employment at any time, with or without Cause, and with or without advance notice. Your employment at-will
status can only be modified in a written agreement approved by Bioventus and signed by you and a duly authorized member of Bioventus. 
 Base Salary and
Employee Benefits 
 Your base salary will be paid at the initial annual rate of $624,000, less payroll deductions and withholdings. You will be
paid your base salary on a bi-weekly basis, on Bioventus’ normal payroll schedule. You will be reimbursed for expenses that are normal and customary for your role and follow applicable Bioventus policies. As an exempt salaried employee, you
will be required to work Bioventus’ normal business hours, and such additional time as appropriate for your work assignments and position. You will not be eligible for overtime premiums. 

 Anthony P. Bihl III 

July 20, 2016 
  Page
 2
 
  
 You will be eligible to participate
in Bioventus’ health and welfare, group insurance, retirement and other employee benefit plans, programs and arrangements (pursuant to the terms and conditions of the benefit plans and applicable policies) as are made generally available from
time to time to executives of the Company. 
 You will be eligible for 20 days of vacation per year. Going forward, you will earn any additional
vacation according to the Bioventus vacation policy. 
 Annual Performance Bonus and Merit Planning 

In this position, you will be eligible to participate in the Bioventus Inc. Senior Executive Incentive Bonus Plan (or any sub-plan thereof or any other bonus
program as determined by the Company and/or Bioventus Inc. from time to time) (the “Executive Incentive Plan”) at an annual target of one hundred percent (100%) of your annual base salary (the “Annual
Bonus”). The Executive Incentive Plan may include components of your personal performance as well as Bioventus’ business objectives. The terms and conditions of your Annual Bonus will be set forth in the Executive Incentive Plan
documents. 
 Your performance will be reviewed on a yearly basis by the Board. At that time, your salary will be reviewed along with your performance to
determine any adjustment to your base salary. 
 IPO and Annual Equity Awards 

In connection with the IPO, you will be granted an option to purchase shares of Class A common stock in amounts to be determined by the Board or the
Compensation Committee thereof (the “Compensation Committee”). 
 In addition, during your employment with the Company
you will be eligible to receive additional annual or other equity compensation awards (“Annual Equity Awards”) as determined by the Board or the Compensation Committee. The terms and conditions of any such Annual
Equity Awards shall be determined by the Board or the Compensation Committee, consistent with the terms of the Bioventus Inc. 2016 Incentive Award Plan (or any successor thereto) and a written award agreement between you and Bioventus Inc. 

Certain Definitions 
 For purposes of this Agreement, the
following definitions will apply: 
 (1) Definition of Change in Control. A “Change in Control” shall mean the first
to occur of any of the following: (A) any “person” (as such term is used in sections 13(d) and 14(d) of the Securities Exchange Act of 1934 (the “Exchange Act”)) (other than persons who are owners of the
Company on the Effective Date or its affiliates or permitted transferees) becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of interests in the Company representing more than 50% of the
voting power of the then outstanding interests in the Company; provided that a Change in Control shall not be deemed to occur as a result of a change of ownership resulting from the death of an owner, and a Change in Control shall not be deemed to
occur as a result of a transaction in which the Company becomes a subsidiary of another company and in which the owners of the Company, immediately prior to the transaction, will beneficially own, immediately after the transaction, interests
entitling such owners to more than 50% of all votes to which all owners of the parent company would be entitled in the election of members (without consideration of the rights of any class of membership interests to elect members by a separate class
vote); (B) the consummation of (i) a merger or consolidation of the Company with another company where the owners of the Company, immediately prior to the merger or consolidation, will not beneficially own, immediately after the merger or
consolidation, membership interests (or other equity instruments) entitling such persons to more than 50% of all votes to which all owners of the surviving company would be entitled in the election of members (without consideration of the rights of
any class of membership interests to elect members by a separate class vote); (ii) a sale or other disposition of all or substantially all of the assets of the Company; or (iii) a liquidation or dissolution of the Company; or
(C) during any 12-month period, a majority of the members of the Company’s Board is replaced by individuals whose appointment or election is not endorsed by a majority of the members of the Company’s Board immediately prior to the
date of appointment or election. 

 Anthony P. Bihl III 

July 20, 2016 
  Page
 3
 
  
 (2) Definition of
Cause. “Cause” for the Company to terminate your employment shall exist if you are given written notice detailing the specific Cause and you fail to cure such event to the satisfaction of the Board within 30 days if any of the
following occurs: (A) your being convicted (including a guilty plea or plea of nolo contendere) of any felony or any other crime involving fraud, violence or dishonesty; (B) your commission of or participation in a fraud or act of
dishonesty or misrepresentation against the Company; (C) your violation of any written and fully executed contract or agreement between you and the Company, including without limitation, breach of your Proprietary Information, Inventions,
Non-Competition and Non-Solicitation Agreement (the “Proprietary Information Agreement”); (D) your gross negligence or willful misconduct, (E) your continued and substantial failure to perform your duties to the
Company; or (F) your violation of any material policies, practices, or procedures of Bioventus. The determination that a termination is for Cause shall be made by Bioventus at its sole discretion. 

(3) Definition of Good Reason. “Good Reason” for you to terminate your employment shall mean the occurrence of any one of the
following events without either (x) your express prior written consent or (y) full cure within 30 days after you give written notice to the Company: (i) material diminution in duties or responsibilities; (ii) a material reduction
in your salary, except for across-the-board salary reductions similarly affecting all senior executive officers of the Company; (iii) the relocation of your principal office, or principal place of employment, to a location more than fifty
(50) miles from the location of your principal office or principal place of business as of the Effective Date; or (iv) a failure to pay you earned compensation; provided however, that no event shall constitute grounds for a Good Reason
termination unless you provide written notice to the Company of the event or condition purported to constitute Good Reason within 90 days of the initial existence of such event or condition and you terminate your employment within sixty days after
such notice is provided. 
 Severance Benefits 

(1) If, at any time prior to a Change in Control, the Company terminates your employment without Cause (other than as a result of your death or
disability) then, subject to paragraph (3), below, you shall receive the following severance benefits (the “Severance Benefits”): (i) eighteen (18) months of your base salary in effect on the effective date of
termination (the “Termination Date”), less applicable taxes and withholdings paid in a lump sum payment on or about 60 days following the Termination Date and shall be directly deposited into your account on record with the
Company’s payroll department, or if there is no account on record, shall be made via check made out to ‘Anthony Bihl’ and mailed to your last known address in the Company’s records; (ii) one hundred fifty percent
(150%) of your target Annual Bonus, paid on or about 60 days following the Termination Date; (iii) if you timely elect continued coverage under federal COBRA laws or comparable state insurance laws (“COBRA”),
then the Company shall pay the COBRA premiums necessary to continue your medical and dental insurance coverage in effect for yourself and your eligible dependents on the termination date for the first eighteen (18) months of such coverage
(provided that such COBRA reimbursement shall terminate on such earlier date as you are no longer eligible for COBRA coverage or you become eligible for group health insurance benefits through a new employer). 

(2) If the Company terminates your employment without Cause or you terminate your employment for Good Reason during the two-year period on or
following a Change in Control, then, subject to paragraph (3), below, you shall receive the following severance benefits (the “CIC Severance Benefits”): (i) twenty-four (24) months of your base salary in effect on
the Termination Date, less applicable taxes and withholdings paid in a lump sum payment on or about 60 days following the Termination Date and shall be directly deposited into your account on record with the Company’s payroll department, or if
there is no account on record, shall be made via a check made out to ‘Anthony Bihl’ and mailed to your last known address in the Company’s records; (ii) two hundred percent (200%) of your target Annual Bonus, paid on or
about 60 days following the Termination Date; and (iii) if you timely elect continued coverage under federal COBRA laws or comparable state insurance laws (“COBRA”), then the Company shall pay the COBRA premiums
necessary to continue your medical and dental insurance coverage in effect for yourself and your eligible dependents on the termination date for the first twenty-four (24) months of such coverage; provided that such COBRA reimbursement shall
terminate on such earlier date as you are no longer eligible for COBRA coverage or you become eligible for group health insurance benefits through a new employer. 

(3) Your receipt of the Severance Benefits or CIC Severance Benefits, as applicable, is conditional upon (a) your continuing to comply
with your obligations under your Proprietary Information Agreement; and (b) your executing and delivering an effective, general release of all known and unknown claims in favor of Bioventus, in the Company’s customary form within 45 days
following the Termination Date (and not revoking the release). 

 Anthony P. Bihl III 

July 20, 2016 
  Page
 4
 
  
 Section 409A 

Notwithstanding anything herein to the contrary, this Agreement is intended to be interpreted and applied so that the payment of the benefits set forth herein
shall either be exempt from the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) (together with the Department of Treasury Regulations and other guidance thereunder,
“Section 409A”) or shall comply with the requirements of such provision. After the Termination Date, you shall have no duties or responsibilities that are inconsistent with having a “separation from service” (within
the meaning of Section 409A) as of the Termination Date and, notwithstanding anything in the Agreement to the contrary, distributions upon termination of employment of nonqualified deferred compensation may only be made upon a “separation
from service” (as determined under Section 409A) and such date shall be the Termination Date for purposes of this Agreement. Each payment under this Agreement or otherwise shall be treated as a separate payment for purposes of
Section 409A. In no event may you, directly or indirectly, designate the calendar year of any payment to be made under this Agreement which constitutes a “nonqualified deferral of compensation” (within the meaning of
Section 409A) and to the extent an amount is payable within a time period, the time during which such amount is paid shall be in the discretion of Bioventus. To the extent that any reimbursements are taxable to you, any such reimbursement
payment due to you shall be paid to you on or before the last day of the calendar year following the taxable year in which the related expense was incurred. The reimbursements are not subject to liquidation or exchange for another benefit and the
amount of such reimbursements that you receive in one taxable year shall not affect the amount of such reimbursements that you receive in any other taxable year. Notwithstanding any provision to the contrary in this Agreement, if you are deemed at
the time of your separation from service to be a “specified employee” for purposes of Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the termination benefits to which you are entitled under
this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such portion of your termination benefits shall not be provided to you prior to the earlier of (A) the expiration of the
six-month period measured from the date of your “separation from service” with the Company or (B) the date of your death; upon the earlier of such dates, all payments deferred pursuant to this sentence shall be paid in a lump sum to
you, and any remaining payments due under the Agreement shall be paid as otherwise provided herein. 
 Compliance with Proprietary Information Agreement
and Bioventus Policies 
 You and the Company acknowledge and agree that you are a party to that certain Proprietary Information, Inventions,
Non-Solicitation, and Non-Competition Agreement with Bioventus (the “Proprietary Information Agreement”) which prohibits unauthorized use or disclosure of Bioventus’ proprietary information and contains certain
post-employment non-competition and non-solicitation obligations, among other obligations, and that the Proprietary Information Agreement remains in full force and effect; provided that for purposes of the Proprietary Information Agreement on and
following the IPO the terms “Company” and “Bioventus” will mean, collectively, Bioventus LLC and Bioventus Inc. In addition, you are expected to continue to comply with the Proprietary Information Agreement and that you will
continue to abide by Bioventus’ Code of Conduct and Bioventus’ policies, as may be changed from time to time at Bioventus’ sole discretion. 

Non-Disparagement 
 During and after your employment, you
and Bioventus agree not to make any statement that criticizes, ridicules, disparages, or is otherwise derogatory of the other or is reasonably likely to be harmful to you or Bioventus, or to your or Bioventus’ respective businesses, business
reputations or personal reputations; provided, however, that nothing in this Agreement shall restrict either party from making truthful statements (a) when required by law, subpoena, court order or the like; (b) when requested by a
governmental, regulatory, or similar body or entity; (c) in confidence to a professional advisor for the purpose of securing professional advice; (d) in the ordinary course of performing your or its duties during your employment;
(e) from rebutting any statement made or written about you or it; or (f) from making normal competitive statements about Bioventus’ business or products. 

 Anthony P. Bihl III 

July 20, 2016 
  Page
 5
 
  
 Outside Activities 

Throughout your employment with Bioventus, you may engage in civic and not-for-profit activities so long as such activities do not interfere with the
performance of your duties hereunder or violate the Bioventus Conflict of Interest Policy. 
 Assignment 

This Agreement may be assigned by Bioventus to a person or entity which is an affiliate or a successor in interest to substantially all of the business
operations of Bioventus. Upon such assignment, the rights and obligations of Bioventus hereunder shall become the rights and obligations of such affiliate or successor person. You may not assign your rights or obligations to another entity or
person. 
 Indemnification 
 You shall be entitled to
indemnification to the maximum extent permitted by applicable law and the Bioventus LLC Operating Agreement or Bioventus Inc. Articles of Incorporation or Bylaws, as applicable. At all times during your employment, the Company shall maintain in
effect a directors and officers liability insurance policy with you as a covered officer. The Company shall further provide and pay for the defense of any action, arbitration or mediation (collectively, an “Action”) relative to the
lawful performance of your duties or in connection with your employment at the Company and the existence of such Action or defense shall not provide grounds for termination of your employment. 

Notice of Immunity 
 Notwithstanding any provision of this
Agreement or the Proprietary Information Agreement to the contrary, (i) you shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that is made in confidence to a Federal,
State, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law; (ii) you shall not be held criminally or civilly liable under any Federal or State trade secret law for the
disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (iii) if you file a lawsuit for retaliation by an employer for reporting a suspected
violation of law, you may disclose the trade secret to your attorney and use the trade secret information in the court proceeding, if you file any document containing the trade secret under seal; and do not disclose the trade secret, except pursuant
to court order. 
 Section 280G Parachute Payments 

Notwithstanding any other provision in this Agreement to the contrary, in the event that any payment or benefit received or to be received by you in connection
with a Change in Control or otherwise would be considered an “excess parachute payment” within the meaning of Section 280G of the Code, then such payments and benefits will either be (i) delivered in full or (ii) reduced by
the minimum amount necessary so that all of the remaining payments and benefits will not be subject to the excise tax imposed by Section 4999 of the Code, whichever of the foregoing (i) or (ii) results in the greater net after-tax
value of payment and benefits to you. All determinations regarding the application of this paragraph shall be made by an accounting firm or consulting group with experience in performing calculations regarding the applicability of Sections 280G and
4999 of the Code selected by the Company, and all associated costs will be borne by the Company. 

 Anthony P. Bihl III 

July 20, 2016 
  Page
 6
 
  
 Compensation Recovery Policy

 You acknowledges and agree that, to the extent the Company adopts any clawback or similar policy pursuant to the Dodd-Frank Wall Street Reform and
Consumer Protection Act or otherwise, and any rules and regulations promulgated thereunder, you will take all action necessary or appropriate to comply with such a clawback policy (including, without limitation, entering into any further agreements,
amendments or policies necessary or appropriate to implement and/or enforce such policy). 
 Miscellaneous 

This Agreement, together with your Proprietary Information Agreement and all applicable equity award agreements forms the complete and exclusive statement of
your employment agreement with Bioventus. It supersedes any other agreements or promises made to you by anyone, whether oral or written, including without limitation that certain Offer Letter by and between you and Bioventus LLC dated
November 4, 2013 (other than the Proprietary Information Agreement which remains in effect). Changes in your employment terms, other than those changes expressly reserved to Bioventus’ discretion in this Agreement, require a written
modification approved by Bioventus. This Agreement will bind the heirs, personal representatives, successors and assigns of both you and Bioventus and inure to the benefit of both you and Bioventus, their heirs, successors and assigns. If any
provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable
in a manner consistent with the intent of the parties insofar as possible under applicable law. This Agreement shall be construed and enforced in accordance with the laws of the State of North Carolina without regard to conflicts of law principles.
The parties hereby irrevocably submit to the jurisdiction of the state and federal courts of North Carolina located in or about Raleigh and waive any claim or defense of inconvenient or improper forum or lack of personal jurisdiction under any
applicable law or decision. Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any
successive breach or rights hereunder. This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile or pdf signatures shall be equivalent to original signatures. For the avoidance of doubt, you agree
that in connection with any termination of your employment, you will resign as an officer and as a member of the Board to the extent requested by the Company. 

I am very pleased to offer you continued employment in this position at Bioventus on and following the IPO under the terms described above. I would be happy
to discuss any questions that you may have about the terms of the offer. Please indicate your acceptance of this offer by signing below and returning a copy to my attention at the Company. It will be a pleasure to continue to work with you and
create the future of Bioventus on and following the IPO. 
 Sincerely, 
  

							
	 /s/ Bill Hawkins
	  		  		  	
	 Bill Hawkins
 Chairman of the
Board
  
 Understood and Accepted:

 
	  		  		  	
	 /s/ Anthony P. Bihl III
	  		  	 July 23, 2016
	  	
	Anthony P. Bihl III	  		  	Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}]]